Sobi announces positive Phase 2 NOBLE results of pegcetacoplan in post-transplant recurrence of primary IC-MPGN and C3G

After 12 weeks, 50% of patients treated with pegcetacoplan showed a reduction in C3c staining by two or more orders of magnitude of intensity from baseline. Pegcetacoplan patients showed improvements across key clinical measures, including kidney function and proteinuria. No approved…